RT Journal Article
T1 Design and characterization of intravitreal bevacizumab-loaded PLGA nanoparticles: pharmacokinetic and biodistribution impact
A1 Varela Fernández, Rubén
A1 García Otero, Xurxo
A1 Cuartero Martínez, Andrea
A1 Gómez Lado, Noemí
A1 González Barcia, Miguel
A1 Mondelo García, Cristina
A1 Aguiar Fernández, Pablo
A1 Fernández Ferreiro, Anxo
A1 Otero Espinar, Francisco Javier
K1 Bevacizumab
K1 PLGA
K1 Nanoparticles
K1 Controlled release
K1 Biodistribution
K1 Pharmacokinetics
AB Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) for treating neovascular and oncological conditions, faces challenges in biodistribution and targeted delivery. Nanoparticle-based drug delivery systems have shown promise in enhancing the pharmacokinetic profiles of biologic drugs. This study aimed to develop and characterize bevacizumab-loaded PLGA nanoparticles to modify antibody’s distribution and improve its therapeutic efficacy. Characterization studies, morphological examination, release profile determination, stability and physical properties were conducted. Biodistribution was studied in rats using PET/CT imaging. Optimized nanoparticles were spherical (around 300 nm) and surface charge (about − 20 mV). Encapsulation efficiency and drug loading varied from 75 to 95%. Stability studies demonstrated minimal changes in size and drug content over the studied period. In vitro release exhibited a biphasic pattern, with an initial burst followed by a sustained release phase. In vivo pharmacokinetics and distribution revealed altered antibody distribution by encapsulation into nanoparticles. Safety studies indicated no significant cytotoxicity or adverse effects. The developed bevacizumab nanoparticles demonstrated favorable physicochemical characteristics, stability, and release profiles. These findings warrant further investigation in disease-specific models to elucidate the clinical potential of this nanoparticle-based delivery system for bevacizumab, particularly in enhancing anti-angiogenic effects and overcoming barriers to effective delivery in target tissues.
PB Springer
YR 2025
FD 2025-06-05
LK https://hdl.handle.net/10347/42584
UL https://hdl.handle.net/10347/42584
LA eng
NO Varela-Fernández, R., García-Otero, X., Cuartero-Martínez, A. et al. Design and characterization of intravitreal bevacizumab-loaded PLGA nanoparticles: pharmacokinetic and biodistribution impact. Drug Deliv. and Transl. Res. (2025). https://doi.org/10.1007/s13346-025-01891-z
NO Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.
NO This work was partially supported by Ministry of Science and Innovation of Spain (MICINN) [PID2022-142350OB-C21], Xunta de Galicia [Grupo de Referencia Competitiva, ED431C 2021/26 and IN607A 2023/04, IN607D-2021/001] and Instituto de Salud Carlos III (ISCIII, Spain) through PI20/00719. X. García-Otero acknowledge the support of Xunta de Galicia through the postdoctoral fellowship [ED481B-2023-063].
DS Minerva
RD 23 abr 2026